20:23 , Oct 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
21:18 , Jul 31, 2018 |  BC Innovations  |  Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
21:59 , May 25, 2018 |  BC Extra  |  Preclinical News

Activating astrocytes to enhance memory

In a paper published in Cell , researchers at The Hebrew University of Jerusalem showed that activating astrocytes in the hippocampus, rather than direct neuronal activation, could improve memory. Previous studies have shown that astrocytes...
19:36 , Dec 6, 2016 |  BC Innovations  |  Distillery Techniques

Imaging

TECHNOLOGY: PET A clozapine-based PET imaging agent that binds DREADD-expressing neurons could help monitor the engraftment of neuronal transplants for neurological diseases. The PET agent consisted of 11 C radionuclide-labeled clozapine-N-oxide, which has a binding...
07:00 , Apr 11, 2016 |  BioCentury  |  Regulation

Tolerable uncertainty

Acadia Pharmaceuticals Inc. may have found a sensitive endpoint for Nuplazid pimavanserin in a condition lacking good measures by adapting a validated but broader scale. Although an FDA advisory committee was uncertain how much real-world...
08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Neurology INDICATION: Parkinson's disease (PD) Mouse studies suggest inhibiting thalamostriatal terminal activity could help treat Parkinson's disease (PD). Levels of thalamic input to indirect-pathway and direct-pathway medium spiny neurons (MSNs) were higher and lower, respectively,...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Oncothyreon, Braeburn deal

Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia. Braeburn plans to develop ATI-9242 into a long-acting...
08:00 , Feb 24, 2014 |  BC Week In Review  |  Company News

Jazz Pharmaceuticals sales and marketing update

Jazz launched Versacloz clozapine in the U.S. to treat severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. Versacloz has a wholesale acquisition cost of $734.14...
07:00 , Oct 24, 2013 |  BC Innovations  |  Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...